Dyne Therapeutics Inc (NASDAQ:DYN) has a beta value of 1.09 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $3.02B, closed the last trade at $29.69 per share which meant it lost -$0.04 on the day or -0.13% during that session. The DYN stock price is -59.82% off its 52-week high price of $47.45 and 65.91% above the 52-week low of $10.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.3 million shares traded. The 3-month trading volume is 1.28 million shares.

The consensus among analysts is that Dyne Therapeutics Inc (DYN) is Buy stock at the moment, with a recommendation rating of 1.20. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.87.

Dyne Therapeutics Inc (NASDAQ:DYN) trade information

Sporting -0.13% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the DYN stock price touched $29.69 or saw a rise of 3.76%. Year-to-date, Dyne Therapeutics Inc shares have moved 123.23%, while the 5-day performance has seen it change 4.58%. Over the past 30 days, the shares of Dyne Therapeutics Inc (NASDAQ:DYN) have changed -4.53%. Short interest in the company has seen 9.94 million shares shorted with days to cover at 12.11.

Wall Street analysts have a consensus price target for the stock at $45, which means that the shares’ value could jump 34.02% from current levels. The projected low price target is $18.0 while the price target rests at a high of $55.0. In that case, then, we find that the current price level is -85.25% off the targeted high while a plunge would see the stock lose 39.37% from current levels.

Dyne Therapeutics Inc (DYN) estimates and forecasts

Figures show that Dyne Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -4.90% over the past 6 months, with this year growth rate of 12.66%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -106.26% over the past 5 years.

DYN Dividends

Dyne Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders

Insiders own 0.48% of the company shares, while shares held by institutions stand at 112.41% with a share float percentage of 112.96%. Investors are also buoyed by the number of investors in a company, with Dyne Therapeutics Inc having a total of 290.0 institutions that hold shares in the company. The top two institutional holders are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 8.02 million shares worth more than $283.03 million. As of 2024-06-30, ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC held 9.8961% of shares outstanding.

The other major institutional holder is FCPM III SERVICES B.V., with the holding of over 7.85 million shares as of 2024-06-30. The firm’s total holdings are worth over $276.86 million and represent 9.6804% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 2.58% shares in the company for having 2.63 shares of worth $77.98 million while later fund manager owns 2.1 shares of worth $62.36 million as of Sep 30, 2024 , which makes it owner of about 2.06% of company’s outstanding stock.